MC «Eugenia», Blagoveschensk, RussiaFar Eastern scientific center of physiology and pathology of respiration North-western state medical university named after I. I. Mechnikov, Saint-Petersburg, Rus-sia Abstracts: It is well known that bronchial asthma (BA) is in the leading place in the structure of morbidity of respiratory organs is the most important problem of modern pulmonology.As you know, the nature of the clinical course and severity of BA largely depends on the ac-tivity of the inflammatory process that begins with damage to the bronchial epithelium, disorders of microcirculation and the subsequent interaction of key effector cells and their mediators.BA is accompanied by a systemic response of the organism to inflammation in the lung tis-sue and involved in this type of mediators, including Pro -and anti-inflammatory cytokines, chemokines, leukotrienes, prostaglandins and others, determine the mechanisms of disease develop-ment.In the literature available to us there is a lot of information, details and evidence character-izing the role of cytokines in the development and course of BA. However, these studies presented a lot of data, but they are, in our opinion, do not allow to present a clear picture of the changes of the cytokine profile in asthma, depending on the shape and severity of the disease. In addition, there are difficulties in the interpretation of cytokine regulation in asthma because the pathogene-sis of this disease are «working» complex allergic and non-allergic mechanisms.In this regard, exploring the use of a set of biomarkers of inflammatory activity, in particular of Pro -and antiinflammatory cytokines for evaluation of the prognosis of BA is of great practical importance.Bronchial asthma (BA) is accompanied by a systemic response of the organism to the in-flammation in lung tissue and involved in this type of mediators, including pro -and anti-inflammatory cytokines, chemokines, leukotrienes, prostaglandins and others, determine the mechanisms of disease development.
